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Abstract
Introduction: Gout is the most prevalent arthritis and significantly impacts on function and quality of life. Given
that gout associates with disabling comorbid conditions, it is not clear whether such a complex of diseases
accounts for the increased disability or if gout may play a role by itself. This study aims to evaluate the specific
influence of gout and disease-related features on functional disability and health-related quality of life (HRQoL) in
patients with gout followed in rheumatology clinics.
Methods: A random sample of patients was drawn from clinical registries of 30 rheumatology clinics across Italy.
Sociodemographic, general health and gout-specific variables were collected. Functional disability and HRQoL were
assessed by the health assessment questionnaire (HAQ) and the Physical and Mental Component Summary scores
(PCS and MCS) of the Short Form-36 (SF-36). Crude and adjusted ordinal logistic and linear regression models were
applied to investigate the specific contribution of different variables on HAQ and SF-36 scores. Results are
presented as odds ratio (OR) or mean difference (MD) and 95% confidence intervals.
Results: Out of 446 patients with gout, 90% were males with a mean age of 63.9 years and median disease
duration of 3.8 years; the majority of patients were overweight or obese, and with several comorbidities; 21.1%
showed at least moderate disability; the PCS score was significantly lower than expected age- and gender-matched
samples in the general population, while MCS score was not. After adjusting for potential sociodemographic and
general-health confounders, gout-specific variables significantly impacted on HAQ, including polyarticular
involvement OR 3.82 (1.63, 8.95), presence of tophi OR 1.92 (1.07, 3.43) and recent attacks OR 2.20 (1.27, 3.81).
Consistent results were found for PCS. The impairment of PCS compared to the general population was limited to
patients with features of chronic gout. MCS was only affected by recent attacks (MD -2.72 [-4.58, -0.86]) and
corticosteroid treatment (-3.39 [-5.30,-1.48]).
Conclusions: The data from the KING study confirm that gout impacts on disability and provide evidence for an
independent association of gout and gout-related features with functional outcome and HRQoL. This result
supports the need to improve specific treatment in gout.
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Introduction
Gout is the most common arthritis in adults with a
worldwide prevalence of 1 to 2% [1]. In Italy the preva-
lence of gout is lower, ranging from 0.5 to 0.9%, although
it is rapidly increasing as in other western countries [2,3].
Population aging, increased drug utilisation and changes
in lifestyles and dietary habits may account for this
increase over time [4].
In patients with gout, functional disability [5], impair-
ment of health-related quality of life (HRQoL) and
increased mortality have been reported [6]. Gout therefore
emerges as a major public health issue. However, it is well
known that gout is associated with several cardiovascular
risk factors including hypertension, dyslipidaemia, insulin
resistance, obesity, as well as renal failure [7]. Whether the
impact of gout is related to the disease itself or whether it
primarily arises from associated risk factors and medical
conditions is still unclear [8].
Today, effective treatments are available for gout but it
has not yet been determined whether, in order to mini-
mise long-term detrimental outcomes, its prevention and
management should primarily target risk factors and
comorbidities rather than disease mechanisms [9]. The
relevance of assessing patient-oriented outcomes, such as
functional ability and HRQoL, has been recently recog-
nised by the Outcome Measures in Rheumatology Clinical
Trial (OMERACT) [8,10,11].
Previous case-control and cross-sectional population
studies have shown that HRQoL and functional impair-
ment were mainly due to confounders, including sociode-
mographic characteristics and comorbidities, rather than
due to gout itself [12,13]. These studies did not explore
clinical characteristics in depth and hence drew conclu-
sions on the overall population of patients with gout with-
out determining the influence of specific features of the
disease. Gout has a wide clinical heterogeneity that may
reflect the varying impact on physical ability and HRQoL.
Prognostic studies on convenience samples of patients
with gout investigated the association between disease
characteristics and outcomes; such studies identified as
predictors acute symptoms, presence of tophi, previous
and current joint involvement, and, under specific condi-
tions, urate-lowering treatment (ULT), but they often
selected chronic and refractory gout without controlling
for several confounders [9,12,14-19]. Whether gout and
gout severity variables themselves are independently asso-
ciated with poor functional ability and HRQoL remains to
be confirmed [8].
In 2011 the Italian Society for Rheumatology (SIR)
established the Kick-off of the Italian Network for Gout
(KING), a national multicentre cohort study that recruited
patients with gout selected by random sampling from
rheumatology centres across Italy. Using cross-sectional
data from this ongoing study, this analysis explored the
influence of disease-related features, derived from a
detailed clinical examination, on functional ability and
HRQoL in patients with a clinical diagnosis of gout and
who are followed in rheumatology clinics. Potential con-
founders including sociodemographic variables and gen-
eral health variables, such as comorbidities and lifestyle,
were taken into account. The results of these analyses
allowed one to evaluate the specific impact of gout, across
its spectrum of disease severity, on functional disability
and HRQoL.
Patients and methods
Study design and recruitment
This is a cross-sectional analysis of an ongoing multicentre
cohort study including patients with a clinical diagnosis of
gout from 30 rheumatology centres in Italy (KING Study,
promoted by SIR; NCT01549210) recruited between June
2011 and January 2012. All Italian rheumatology centres
were asked to participate. The cohort is a nationwide
representative sample of patients referred to rheumatology
clinics.
To limit selection bias arising from nonprobability
samples (for example, consecutive sampling) resulting
from the limited time span of recruitment and infrequent
follow-up appointments [20], participants were selected
from clinical registries by random cluster sampling.
Rheumatologists sent a list of all patients registered in
the previous 2 years at their clinics with a diagnosis of
gout. Patients were then randomly selected from these
registries by an independent investigator (CAS) at a cen-
tral facility who also checked for duplicates between cen-
tres by using probability record linkage based on gender,
date and place of birth. The selection complied with the
Italian data protection regulations.
Rheumatologists confirmed from their clinical records
that the patients selected had a diagnosis of gout.
Patients were recruited by telephone following a rigor-
ous contact protocol to optimise recruitment of patients.
Patients included in the study sample did not systemati-
cally differ from the source population in terms of age,
gender and follow-up duration.
A total of 450 patients were recruited but four of them
were excluded because at baseline assessment they did
not meet the inclusion criterion of clinical diagnosis of
gout. The study flowchart is reported in Additional file 1.
The study protocol was approved by the ethics commit-
tees of the following institutions: IRCCS Policlinico
S. Matteo Foundation of Pavia, San Martino Hospital of
Genoa, University Hospital of Bologna, University Hospital
of Ferrara, University Hospital of Firenze, University
Hospital of Foggia, University Hospital of Messina,
University Hospital of Padova, University Hospital of
Palermo, University Hospital of Siena, University Hospital
of Verona, University Hospital of San Camillo, Forlanini
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Hospital of Rome, Humanitas Institute of Milano, G. Pini
institute of Milano, S. Giovanni Battista Hospital of Tor-
ino, Macchi Foundation of Varese, and the local health
authorities of Barletta, Catania, Crotone, Cuneo, Marche,
Milano, Roma, Pescara and Salerno. The study was con-
ducted in accordance with the Declaration of Helsinki,
and each patient provided written informed consent.
Clinical assessment
At baseline all patients underwent full clinical evaluation,
which followed a structured case report form that included
both general health and disease-specific variables.
General variables included sociodemographic data,
lifestyle factors, the food-frequency questionnaire of the
Italian National Institute for Statistics for national
surveys, and comorbidities scored according to the Self-
Administered Comorbidity Questionnaire [21,22]. The
Self-Administered Comorbidity Questionnaire score
ranges from 0 to 36 since it includes 12 medical
problems and allocates 1 point for the presence of each
problem, another point if the patient receives treatment
for it, and an additional point if the problem causes a
limitation in function [21].
Gout-related variables included symptom duration, clas-
sification according to the 1977 preliminary American
College of Rheumatology criteria [23], disease-related
comorbidities (hypertension, dyslipidaemias, diabetes,
cerebrovascular and cardiovascular disease and urinary
stones), pattern of disease (such as number and site of
involved joints, presence and site of tophi), previous and
current treatment for gout, joint examination on 66/68,
measurement of tophi, a 0 to 10 numeric rating scale for
pain, disease severity, general health and serum uric acid
(sUA) concentration.
All patients completed the Italian versions of the
Health Assessment Questionnaire Disability Index
(HAQ-DI) and the Short-Form-36 (SF-36) [24,25].
To limit information bias and to improve overall relia-
bility, all rheumatologists were instructed to collect the
data and clinical measurements by following standard
definitions and operating procedures. All data were also
centrally checked for missing values and inconsistencies
through a standardised procedure of data monitoring
and cleaning.
Variables: outcomes, predictors and confounders
Functional disability assessed by the HAQ-DI was the pri-
mary outcome measure of this analysis. The HAQ-DI is a
self-administered questionnaire validated for several
forms of arthritis including gout and is recommended by
OMERACT [10]. The HAQ-DI score (range 0 to 3) was
categorised into three different classes of functional
disability according to relevant cutoff values proposed by
the developers and as applied in other arthritides: absent
or mild (0 to 1), moderate (>1 to 2) and severe (>2 to 3)
[26,27].
HRQoL measured by the SF-36 questionnaire was the
secondary outcome. The SF-36 is a widely used, self-
administered general health status instrument consisting
of 36 items, which can be scored as two summary
scores: Physical Component Summary (PCS) and Mental
Component Summary (MCS) scores. The summary
scores were normalised to the Italian population, where
the mean score is 50 with a standard deviation of 10
[25,28,29]. A score below the mean score of 50 implies
a lower health status as measured by the PCS and MCS.
Clinically significant difference for the SF-36 summary
scores was set at 2.5 as previously reported [30].
Disease-related variables were used as predictors and
were coded as follows: symptom duration (>5 years),
cumulative joint involvement (1 joint, monoarticular; 2 to
4 joints, oligoarticular; >4 joints, polyarticular), number of
attacks in the last year, attacks in the last month, presence
of tophi, number of swollen joints, number of tender
joints, sUA (<5 mg/dl; ≥5 to 6 mg/dl; ≥6 to 7 mg/dl; >7
mg/dl) [31], current ULT, current nonsteroidal anti-
inflammatory drugs or colchicine use, and systemic corti-
costeroid use at any time (previous or current).
The following general variables were classified as con-
founders: age, sex (male as reference), education (none or
primary; secondary, upper secondary and tertiary educa-
tion), employment (employed; unemployed; retired;
unknown/other), smoking (current smoker; nonsmoker
or exsmoker), body mass index category (underweight,
≤18.5; normal weight, 18.5 to 24.9; overweight, 25 to
29.9; obesity, ≥30), high alcohol consumption (>0.5 litres
of wine per day, beer more than occasionally or spirits
more than occasionally).
Sample size was estimated based on the primary
objective of the cohort study; that is, the evaluation of a
prognostic model of progression of functional disability
after 12 months of follow-up including a training set of
300 patients and a validation set of 150 patients.
Statistical methods
Descriptive measures of sociodemographic, general
health and gout-related variables are presented as the
absolute and relative frequency, mean and standard
deviation or median and interquartile range based on
their type and distribution.
Age-stratified and gender-stratified Italian normative
data for the SF-36 were used to calculate the expected
HRQoL for a standard population of similar age and gen-
der structure [28]. The relationship between predictors
and the HAQ score was modelled using ordinal regression
[32]. Proportionality of odds across the HAQ groups was
checked for each regression. Results are presented as odds
ratios and 95% confidence intervals. The relationship
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between predictors and secondary outcomes (PCS and
MCS) were analysed using linear regression models and
the results are presented as mean difference and 95% con-
fidence intervals.
To evaluate the specific effect of gout-related variables,
three different set of models were used for each outcome:
unadjusted; adjusted for age and gender; and adjusted for
age, gender, education, employment, body mass index,
smoking, alcohol consumption and comorbidities. To
compare expected with observed PCS scores, mean (and
95% confidence interval) PCS scores according to differ-
ent disease characteristics (disease duration, joint invol-
vement, presence of tophi and number of attacks) and
presence of comorbidities were obtained fitting fully
adjusted linear regression models.
The overall percentage of missing information was less
than 1% for variables included in the analyses. Given the
high number of variables (n = 21), complete case analysis
would have included only 83% of patients. Missing data
were imputed using chained equations [33] and the fully
adjusted analyses were performed on 10 multiple imputed
datasets.
Analyses were performed using STATA software
package (2009, release 11; StataCorp, TX, USA).
Results
A total of 446 patients with a clinical diagnosis of gout
were included in this analysis. The main sociodemographic,
general health and disease-related variables are summarised
in Table 1.
The study sample included a majority of male (90%)
patients, with an overall mean (standard deviation) age of
63.9 (11.6) years, and a high frequency of Caucasian sub-
jects (99%). Male patients were younger than female
patients with a mean (standard deviation) age of 63.6
(11.6) and 66.9 (11.8) years, respectively. The education
background of the patients was mainly secondary school
or lower. The majority of patients were overweight or
obese and showed a high prevalence of high alcohol
intake. More than 90% of patients had at least one
comorbid condition according to the Self-Administered
Comorbidity Questionnaire, mostly of a metabolic or car-
diovascular nature. Most subjects had more than one
comorbid condition with a median number (interquartile
range) of 3 (1 to 4). More than 92% of patients fulfilled
the preliminary American College of Rheumatology cri-
teria for disease classification (22% only based on crystal
identification), and showed a median of 3.8 years of dis-
ease duration and a high prevalence of oligoarticular or
polyarticular disease. About 30% of patients experienced
an attack of gout within 1 month prior to the clinical eva-
luation, and 214 out of 410 (52.2%) had sUA levels above
6 mg/dl, despite 361/446 (80.9%) being on ULT.
According to the HAQ-DI score, at least moderate func-
tional disability was observed in 94 out of 444 (21.1%)
patients, of whom 72 (16.22%) showed moderate disability
and 22 (4.95%) showed severe disability (Figure 1). The
median (interquartile range) HAQ score was 0.25 (0 to
0.875). Overall, the physical components summarised
by the PCS score were reduced as compared with the
Table 1 Patients’ characteristics
Characteristic
Sex (male) 403/446 (90.4)
Age (years) 63.9 (11.6)
Employment
Employed 137 (30.7)
Unemployed 28 (6.3)
Retired 226 (59.6)
Unknown/not declared 15 (3.4)
Education
No or primary 158 (35.9)
Secondary 121 (27.5)
Upper secondary 123 (27.9)
Tertiary 38 (8.6)
Current smokers 72/444 (16.2)
Body mass index 28.0 (4.1)
High alcohol consumers 160 (36.4)
Comorbidities 3 (1 to 4)
Hypertension 313 (70.3)
Renal failure 73 (16.4)
Osteoarthritis 249 (55.9)
Cardiovascular disorders 119 (26.8)
Diabetes 64 (14.4)
Liver disorders 36 (8.1)
Neoplasms 28 (6.29)
Sangha comorbidity index (0 to 36) 4 (2 to 7)
Fulfils preliminary ACR criteria 411/445 (92.4)
Disease duration (years) 3.8 (1.5 to 10.1)
Joint involvement
Monoarticular (1 joint) 95(21.5)
Oligoarticular (2 to 4 joints) 264 (59.7)
Polyarticular (>4 joints) 83 (18.8)
Swollen joints (0 to 66) 0 (0 to 1)
Tender joints (0 to 68) 1 (0 to 3)
Presence of tophia 87 (19.9)
Number of flares (12 months) 1 (0 to 3)
Flare (previous month) 132 (29.9)
Serum urate level (mg/dl)b 6.3 (1.7)
Previous corticosteroids 125 (28.0)
Current NSAIDs or colchicine 189 (42.4)
Allopurinol 303 (67.9)
Febuxostat 60 (13.4)
Data presented as n (%), mean (standard deviation) or median (interquartile
range). ACR, American College of Rheumatology; NSAID, nonsteroidal anti-
inflammatory drug. Data available for a437 subjects and b410 subjects.
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expected score for the age-matched and gender-matched
general population (Figure 1). The MCS score did not dif-
fer from that for the general population.
Associations of sociodemographic, general health and
disease-specific variables with functional disability and
HRQoL were evaluated. The results of crude and adjusted
analyses are presented in Tables 2 and 3.
Among sociodemographic data, older age, female gen-
der and lower education significantly affected functional
disability and the physical component of the SF-36 while
only female gender influenced the mental component.
General health variables that significantly associated
with higher HAQ-DI and lower PCS scores in age-
adjusted and gender-adjusted models included comorbid-
ities, overweight and obesity. Obesity was also associated
with a statistically and clinically relevant lower MCS score.
Disease-related variables were strongly associated with
functional disability and the physical component in the
unadjusted analyses. After adjusting for age, gender and
the other confounders, variables indicating chronic dis-
ease (disease duration, polyarticular joint involvement,
presence of tophi) and uncontrolled joint inflammation
(swollen and tender joints, attacks in the last months
and current use of nonsteroidal anti-inflammatory drugs
or colchicine) still showed statistically and clinically sig-
nificant associations with the HAQ-DI and PCS scores.
The MCS score was only influenced by acute symptom-
related variables.
Neither uncontrolled sUA nor ULT were associated with
HAQ-DI or PCS outcomes in the fully adjusted analyses,
even though subjects with high sUA levels (>7 mg/dl)
showed statistically and clinically meaningful worse out-
comes the analyses adjusted for age and gender.
Adjusted mean PCS scores, stratified by category of dis-
ease severity and presence of comorbidity, showed that
subjects with monoarticular disease, absence of tophi and
intercritical disease did not show significant impairment in
the physical component of the PCS (Figure 2).
Discussion
Our results show that functional and HRQoL impairment
observed in gout patients is not only due to general
health variables, such as associated risk factors and
comorbidities, but is also influenced by the activity and
severity of several disease-related variables. Two studies
previously attempted to answer the same question as the
current study at a population level, suggesting that gout
is not independently associated with HRQoL impairment.
The first, a case-control study carried out in the United
Kingdom using electronic records of general practi-
tioners, reported an association between gout and
impaired overall quality of life in a univariable analysis.
Association was only evident in the physical domain of
the World Health Organization Quality of Life - BREF
instrument after adjusting for age, gender, body mass
index, and medical/musculoskeletal comorbidities [12].
Figure 1 Health-related quality of life in gout patients compared with that expected for Italian normative population. Bar chart: Short
Form-36 subscales and summary scales - physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social
functioning (SF), role emotional (RE), mental health (MH), Physical Component Summary (PCS) and Mental Component Summary (MCS) scale
scores. Line chart: normative data for Italian population. Error bars represent 95% confidence intervals (CIs). Nonoverlapping CIs indicate
statistically significant impairment.
Scirè et al. Arthritis Research & Therapy 2013, 15:R101
http://arthritis-research.com/content/15/5/R101
Page 5 of 10
This association was only slightly statistically significant
and of unclear clinical relevance. A second population-
based survey, carried out from the US veterans database,
found poorer HRQoL and higher functional limitation in
patients with gout in unadjusted analyses that disap-
peared after controlling sociodemographic and comor-
bidity data [13]. These population studies, even limited
by low response rates and incomplete clinical assessment,
certainly captured the real distribution of gout severity,
including a higher prevalence of cases with mild disease.
In our study we included a probability sample of patients
with a clinical diagnosis of gout confirmed by a rheuma-
tologist and we assessed functional disability and HRQoL
using the tools recommended by OMERACT [10].
Table 2 Association between sociodemographic, general health and disease-specific variables to functional disabilitya
Variable HAQ-DI
Crude OR (95% CI) Adjusted OR (95% CI)b Adjusted OR (95% CI)c
Sociodemographic
Gender (female vs. male) 6.27 (3.37, 11.64)
Age (5 years) 1.28 (1.15, 1.44)
Education
No or primary Reference
Secondary 0.48 (0.27, 0.84) 0.66 (0.36, 1.20)
Upper secondary 0.21 (0.10, 0.42) 0.27 (0.13, 0.56)
Tertiary 0.17 (0.05, 0.57) 0.19 (0.05, 0.73)
Employment
Employed Reference
Unemployed 5.85 (2.21, 15.48) 2.49 (0.85, 7.31)
Retired 3.57 (1.81, 7.03) 2.21 (0.92, 5.28)
Unknown - -
General health variables
Comorbidity index 1.22 (1.15, 1.29) 1.16 (1.09, 1.24)
Body mass index
Normal Reference
Overweight 1.82 (0.90, 3.68) 2.44 (1.14, 5.22)
Obese 2.71 (1.28, 5.73) 4.02 (1.78, 9.07)
Current smokers 0.99 (0.53, 1.85) 1.37 (0.71, 2.64)
High alcohol consumers 0.96 (0.59, 1.54) 1.46 (0.87, 2.45)
Gout-related variables
Disease duration (>5 years) 1.98 (1.24, 3.14) 2.12 (1.30, 3.46) 2.03 (1.22, 3.40)
Joint involvement
Monoarticular Reference
Oligoarticular (2 to 4 joints) 1.75 (0.89, 3.45) 1.99 (0.96, 4.09) 1.49 (0.70, 3.16)
Polyarticular (>4 joints) 3.67 (1.72, 7.82) 4.88 (2.17, 10.97) 3.82 (1.63, 8.95)
Number of attacks last year 1.10 (1.05, 1.17) 1.13 (1.06, 1.20) 1.11 (1.04, 1.18)
Attacks last month 1.89 (1.17, 3.04) 2.33 (1.40, 3.89) 2.20 (1.27, 3.81)
Presence of tophi 2.14 (1.28, 3.59) 2.06 (1.19, 3.56) 1.92 (1.07, 3.43)
Number of swollen joints 1.25 (1.16, 1.35) 1.25 (1.15, 1.35) 1.23 (1.13, 1.33)
Number of tender joints 1.14 (1.10, 1.19) 1.13 (1.08, 1.18) 1.10 (1.06, 1.15)
Serum uric acid
<5 mg/dl Reference
5 to 6 mg/dl 1.18 (0.57, 2.42) 1.25 (0.58, 2.69) 1.24 (0.56, 2.74)
6 to 7 mg/dl 0.94 (0.42, 2.10) 1.20 (0.51, 2.79) 0.83 (0.34, 2.06)
>7 mg/dl 1.72 (0.89, 3.32) 2.49 (1.22, 5.06) 1.81 (0.87, 3.74)
Urate-lowering treatment 1.02 (0.57, 1.81) 1.11 (0.59, 2.09) 1.06 (0.55, 2.03)
Current NSAIDs or colchicine 3.17 (1.89, 5.33) 3.24 (1.87, 5.61) 2.57 (1.40, 4.72)
Previous corticosteroids 1.87 (1.15, 3.05) 1.76 (1.04, 2.97) 1.64 (0.93, 2.89)
NSAID, nonsteroidal anti-inflammatory drug. aAssessed by the Health Assessment Questionnaire Disability Index (HAQ-DI). bAdjusted for age and gender.
cAdjusted for age, gender, comorbidities, body mass index, smoking, high alcohol consumption, education and employment (on 10 imputed datasets).
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Table 3 Association between sociodemographic, general health and disease-specific variables to health-related
quality of lifea
SF-36 PCS SF-36 MCS
Crude MD
(95% CI)
Adjusted MD
(95% CI)b
Adjusted MD
(95% CI)c
Crude MD
(95% CI)
Adjusted MD
(95% CI)b
Adjusted MD
(95% CI)c
Sociodemographic
variables
Gender (female vs. male) -7.37 (-10.67,
-4.08)
-3.45 (-6.44, -0.45)
Age (5 years) -1.04 (-1.45, -0.64) -0.15 (-0.52, 0.23)
Education
No or primary Reference Reference
Secondary 1.44 (-0.96, 3.84) -0.26 (-2.69, 2.18) 0.52 (-1.68, 2.73) 0.42 (-1.90, 2.73)
Upper secondary 5.71 (3.32, 8.10) 3.95 (1.48, 6.41) 2.15 (-0.06, 4.35) 2.11 (-0.24, 4.45)
Tertiary 5.40 (1.84, 8.97) 3.84 (0.26, 7.41) 2.30 (-0.98, 5.58) 2.46 (-0.94, 5.86)
Employment
Employed Reference Reference
Unemployed -6.05 (-10.16,
-1.94)
-3.10 (-7.31, -1.11) -2.74 (-6.50, 1.03) -1.83 (-5.77, 2.12)
Retired -4.59 (-6.69, -2.49) -1.99 (-4.85, 0.88) -0.21 (-2.13, 1.71) 0.34 (-2.34, 3.01)
Unknown - - - -
General health
variables
Comorbidity index -1.12 (-1.34, -0.90) -0.98 (-1.22, -0.74) -0.58 (-0.80, -0.37) -0.62 (-0.85, -0.39)
Body mass index
Normal Reference Reference
Overweight -2.4 7 (-4.97, 0.04) -2.98 (-5.38, -0.58) -1.06 (-3.32, 1.20) -1.45 (-3.71, 0.81)
Obese -4.87 (-7.73, -2.01) -5.79 (-8.51, -3.06) -2.35 (-4.92, 0.22) -2.72 (-5.29, -0.16)
Current smokers 0.04 (-2.60, 2.67) -0.90 (-3.45, 1.64) 0.47 (-1.9, 2.84) 0.3 (-2.08, 2.68)
High alcohol consumers 0.57 (-1.47, 2.60) -0.58 (-2.56, 1.39) -0.94 (-2.77, 0.88) -1.33 (-3.17, 0.52)
Gout-related
variables
Disease duration (>5 years) -2.54 (-4.49, -0.58) -2.37 (-4.25, -0.49) -1.70 (-3.45, 0.05) -2.54 (-4.29, -0.79) -2.61 (-4.35, -0.86) -2.08 (-3.79, -0.37)
Joint involvement
Monoarticular Reference Reference
Oligoarticular (2 to 4 joints) -3.13 (-5.53, -0.73) -3.35 (-5.64, -1.06) -2.22 (-4.38, -0.07) 0.40 (-1.78, 2.57) 0.27 (-1.90, 2.44) 0.96 (-1.18, 3.10)
Polyarticular (>4 joints) -5.66 (-8.69, -2.62) -5.92 (-8.82, -3.01) -3.79 (-6.55, -1.04) -1.05 (-3.80, 1.70) -1.25 (-4.00, 1.50) 0.42(-2.30, 3.16)
Number of attacks last year -0.70 (-0.94, -0.47) -0.71 (-0.93, -0.49) -0.56 (-0.77, -0.36) -0.45 (-0.66, -0.24) -0.44 (-0.65, -0.23) -0.34 (-0.55, -0.13)
Attacks last month -8.18 (-10.15,
-6.20)
-8.62 (-10.49, -6.76) -8.13 (-9.88, -6.38) -3.22 (-5.09, -1.35) -3.33 (-5.20, -1.47) -2.72 (-4.58, -0.86)
Presence of tophi -4.72 (-7.15, -2.30) -4.16 (-6.50, -1.83) -3.20 (-5.41, -0.99) 0.56 (-1.62, 2.75) 0.71 (-1.47, 2.89) 1.26 (-0.88, 3.40)
Number of swollen joints -0.91 (-1.17, -0.65) -0.78 (-1.04, -0.53) -0.54 (-0.79, -0.29) -0.40 (-0.64, -0.16) -0.37 (-0.62, -0.13) -0.20 (-0.45, 0.04)
Number of tender joints -0.64 (-0.79, -0.49) -0.58 (-0.73, -0.42) -0.39 (-0.55, -0.24) -0.38 (-0.52, -0.24) -0.36 (-0.51, -0.21) -0.24 (-0.39, -0.09)
Serum uric acid
<5 mg/dl Reference Reference
5 to 6 mg/dl -0.09 (-3.14, 2.96) -0.15 (-3.06, 2.76) -0.60 (-3.24, 2.02) -0.2 (-2.97, 2.57) -0.23 (-2.99, 2.52) -0.66 (3.19, 1.86)
6 to 7 mg/dl -0.12 (-3.09, 2.86) -0.60 (-3.46, 2.26) 0.48 (-2.32, 3.29) -1.68 (-4.38, 1.03) -1.71 (-4.42, 0.99) -0.75 (-3.55, 2.04)
>7 mg/dl -1.78 (-4.56, 0.99) -2.95 (-5.63, -0.28) -2.06 (-4.51, 0.38) -1.45 (-3.98, 1.07) -1.78 (-4.31, 0.76) -1.00 (-3.39, 1.38)
Urate-lowering treatment 0.41 (-2.05, 2.87) 0.37 (-2.01, 2.75) 0.49 (-1.71, 2.69) 0.27 (-1.94, 2.47) 0.06 (-2.16, 2.27) 0.03 (-2.12, 2.19)
Current NSAIDs or colchicine -7.03 (-8.95, -5.11) -6.67 (-8.52, -4.82) -5.47 (-7.38, -3.56) -2.79 (-4.57, -1.00) -2.53 (-4.32, -0.75) -2.13 (-4.04, -0.23)
Previous corticosteroids -5.10 (-7.26, -2.95) -4-67 (-6.75, -2.59) -3.51 (-5.46, -1.26 -4.15 (-6.06, -2.23) -3.90 (-5.83, -1.98) -3.39 (-5.30, -1.48)
aAssessed by the Short Form-36 (SF-36) questionnaire, physical and mental summary score. CI, confidence interval; MCS, Mental Component Summary; MD, mean
difference; PCS, Physical Component Summary. aAdjusted for age and gender. bAdjusted for age, gender, comorbidities, body mass index, smoking, high alcohol
consumption, education and employment (on 10 imputed datasets).
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All patients were also directly assessed for sociodemo-
graphic, lifestyle and clinical variables in order to control a
number of potential confounders. The results of the fully-
adjusted models indicated that the association between
disease-specific variables and functional disability, as
assessed by HAQ-DI and PCS, are both statistically and
clinically meaningful. To estimate the specific influence of
disease-related variables on the PCS compared with the
expected from the general population, the multivariable
models were applied to obtain the adjusted mean PCS
score for different levels of disease severity variables. The
subgroup of patients with monoarticular disease, a low
number of attacks and an absence of tophi did not show
any significant impairment of the physical component of
the SF-36 when compared with that of the general popula-
tion. This result may partially explain the weakness of
independent association between gout and disability or
poor HRQoL in the general population given that popula-
tion-based studies are likely to have a considerable num-
ber of subjects with a single attack or intercritical gout
[12,13]. Disease-associated impairment of HRQoL thus
seems to be related to a subgroup of patients with chronic
gout while the physical impairment of subjects with mild
disease is mainly due to general risk factors and concur-
rent medical conditions.
In our study, another significant finding is the identifica-
tion of a number of disease-related factors associated with
a worse outcome. The number of joints cumulatively
involved was one of the major factors independently asso-
ciated with increased presence of functional disability and
worsening of the SF-36 physical component. This has been
previously demonstrated for the number of involved joints
against the PCS and MCS and for the disease-specific
HRQoL instrument Gout Impact Scale [8,17]. Other
findings are also highly consistent with the existing
literature: the presence of tophi, as well as factors indicat-
ing active disease (such as number of swollen and tender
joints, frequency of attacks) [16,17,34], have been reported
as major predictors of functional disability [14,16] and
poor HRQoL [16,34]. Our data confirm such associations
and provide fully adjusted estimates by analysing the
impact of every single variable using clinically relevant cut-
off values or meaningful differences from tools validated
for gout.
Our study confirms the lack of association between
cross-sectional sUA levels and HAQ-DI or SF-36 dimen-
sions [12,14,16], while other studies reported a significant
association with longitudinal levels of sUA [9,34]. This
result might be partially explained by the fact that patients
with more severe disease might be treated more aggres-
sively, and therefore they exhibit a relatively better level of
sUA than patients with mild disease. Furthermore, despite
the relevance of sUA as a biomarker in gout [11], the
effect on the outcome of severe disease is likely to be
reached by a persistent control of sUA over time [35].
The mental component of the SF-36 is not generally
affected in patients with gout [12,13,17,35]. Main clinical
characteristics influencing the MCS score are variables
of acute disease such as gout attacks, tender joints and
the daily use of nonsteroidal anti-inflammatory drugs
[12,16]. Our results confirmed these previous findings
and further showed that the use of systemic glucocorti-
coids may also impact on the mental component of the
SF-36. This finding, already reported by Roddy and col-
leagues [12], should be interpreted in the context of
more severe disease leading to the prescription of corti-
costeroids rather than as an effect on disease severity -
an issue that is still to be resolved.
This study has some limitations. Results may not be
translated to the whole population of gout patients since
Figure 2 Mean Physical Component Summary scores according to different disease characteristics and presence of comorbidities. Error
bars represent 95% confidence intervals (CIs). CIs not crossing the expected value of 50 (dashed line) indicate statistically significant impairment..
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participants were recruited from the registries of rheuma-
tology clinics that usually follow up patients with chronic
disease and atypical presentations. However, demo-
graphic and clinical characteristics are consistent with
those reported in a recent descriptive study carried out in
a nationwide representative primary care register in Italy
[2]. Given that the majority of rheumatology clinics were
hospital based, recruitment of patients can be further
biased towards gout patients with more severe comorbid-
ities. However, a detailed clinical evaluation in a rheuma-
tological setting has included patients with accurate
diagnosis of gout (92% fulfilled the preliminary American
College of Rheumatology criteria) and allowed analyses
for different levels of disease severity. The cross-sectional
design is essentially descriptive and exploratory since it
does not allow for the ascertainment of temporal rela-
tionship between clinical characteristics, treatment or
modification of risk factors on outcomes.
Conclusions
The KING study provides evidence for an independent
association of gout and gout-related characteristics with
functional outcome and HRQoL. In patients with chronic
gout, the study also confirms the well-known influence of
sociodemographic characteristics and comorbidities on
the disease outcomes. These findings support the need
for an integrated therapeutic approach, which combines
specific disease control to limit progression of acute or
intercritical to chronic gout and management of conco-
mitant risk factors and medical conditions.
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